| (Values in U.S. Thousands) | Apr, 2025 | Apr, 2024 | Apr, 2023 | Apr, 2022 | Apr, 2021 |
| Sales | 33,537,000 | 32,364,000 | 31,227,000 | 31,686,000 | 30,117,000 |
| Sales Growth | +3.62% | +3.64% | -1.45% | +5.21% | +4.16% |
| Net Income | 4,662,000 | 3,677,000 | 3,758,000 | 5,040,000 | 3,606,000 |
| Net Income Growth | +26.79% | -2.16% | -25.44% | +39.77% | -24.70% |
Medtronic Inc (MDT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions.
Fiscal Year End Date: 04/30